TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA

Edward V. Loftus  ¹     Joana Torres  ²     Gareth Parkes  ^{3, 4}     Ken Takeuchi  ⁵     Si Xuan  ⁶     James Crooks     Justin Klaff     Yuri Sanchez Gonzalez     Silvio Danese  ^7    
1 Mayo Clinic College of Medicine and Science, Rochester, United States
² Hospital Beatriz Ângelo, Lisbon, Portugal
³ Barts and the London School of Medicine and Dentistry, London, United Kingdom
⁴ Barts Health NHS Trust, London, United Kingdom
⁵ IBD Center, Tsujinaka Hospital Kashiwanoha, Kashiwa, Japan
⁶ AbbVie, Inc., North Chicago, United States
⁷ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy

Topic
IBD

Session
Hit the road JAK: Part 2

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)